In breast cancer, positivity for KRT19 in the metastatic setting may range between 30 and 80%, whereas in patients with non-metastatic breast cancer, percentages are generally around 20%, although some studies reported higher values up to 60% [155,156,157]. The gene discussed is KRT19; the disease is breast carcinoma.